Skip to main content
NCBI home page
Mediators of Inflammation logoLink to Mediators of Inflammation
. 1999;8(6):277–286. doi: 10.1080/09629359990289

Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission.

T Robak 1, A Wierzbowska 1, M Błasińska-Morawiec 1, A Korycka 1, J Z Błoński 1
PMCID: PMC1781813  PMID: 10815616

Abstract

We have investigated the serum concentrations of interleukin-6 (IL-6) and two IL-6 family cytokines-oncostatin M (OSM) and leukemia inhibitory factor (LIF)-in 63 patients with B-cell chronic lymphocytic leukemia (B-CLL) and 17 healthy controls using the enzyme-linked immunosorbent assay (ELISA) method. Simultaneously, we measured the serum levels of the soluble forms of two subunits of the IL-6 receptor complex-ligand binding glycoprotein 80 (sIL-6R) and glycoprotein 130 (sgp130). The cytokines and receptors were evaluated in 25 untreated patients and 38 patients treated with cladribine (2-CdA), as well as in 17 healthy controls. We have correlated the serum levels of these proteins with Rai's clinical stage of the disease, the response to 2-CdA treatment and some hematological parameters. We have also evaluated the correlation of the IL-6 serum level with the concentration of OSM and IL-6 soluble receptors. IL-6 was measurable in 62/63 (98.4%), OSM in 20/25 (80%) of untreated and 14/38 (37.8%) of the treated patients. sIL-6R and sgp130 were detectable in all 63 patients and LIF in none of the CLL patients. IL-6 serum level in untreated patients was not significantly different as compared to its concentration in the control group (P>0.05). However, in the patients treated with 2-CdA the IL-6 level was significantly lower (P<0.02), and the lowest concentration was found in the patients with complete remission (CR; median 1.4pg/ml; P<0.02). The concentration of sIL-6R was significantly higher in untreated (median 61.8 ng/ml) and treated (median 50.1 ng/ml) CLL patients when compared to normal persons (median 41.2 ng/ml; P=0.04; P<0.001, respectively). There was no difference between the sIL-6R levels in the patients with CR and the healthy controls. In non-responders sIL-6R concentration was the highest and similar to its level in the untreated patients. OSM level was higher in the untreated patients (median 1.8pg/ml) than in the normal controls (median 0.0pg/ml; P<0.001) and in the CR patients (median 0.0pg/ml; P<0.03). The serum concentration of sgp130 was similar in the untreated (median 480 pg/ml) and treated (median 470 pg/ml) patients, as well as in the healthy persons (median 420 pg/ml; P>0.05). We have found significant positive correlation between the levels of sIL-6R and the lymphocytes count in CLL patients (p=0.423; P<0.001). In addition, sIL-6R and OSM serum concentrations correlated also with CLL Rai stage. In conclusion, the serum level of IL-6, OSM and sIL-6R, but not LIF and sgp130, are useful indicators of CLL activity.

Full Text

The Full Text of this article is available as a PDF (231.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aderka D., Maor Y., Novick D., Engelmann H., Kahn Y., Levo Y., Wallach D., Revel M. Interleukin-6 inhibits the proliferation of B-chronic lymphocytic leukemia cells that is induced by tumor necrosis factor-alpha or -beta. Blood. 1993 Apr 15;81(8):2076–2084. [PubMed] [Google Scholar]
  2. Aguilar-Santelises M., Loftenius A., Ljungh C., Svenson S. B., Andersson B., Mellstedt H., Jondal M. Serum levels of helper factors (IL-1 alpha, IL-1 beta and IL-6), T-cell products (sCD4 and sCD8), sIL-2R and beta 2-microglobulin in patients with B-CLL and benign B lymphocytosis. Leuk Res. 1992 Jun-Jul;16(6-7):607–613. doi: 10.1016/0145-2126(92)90009-v. [DOI] [PubMed] [Google Scholar]
  3. Brugiatelli M., Claisse J. F., Lenormand B., Morabito F., Callea V., Malloum K., Chevret S., Binet J. L., Dighiero G., Travade P. Long-term clinical outcome of B-cell chronic lymphocytic leukaemia patients in clinical remission phase evaluated at phenotypic level. Br J Haematol. 1997 Apr;97(1):113–118. doi: 10.1046/j.1365-2141.1997.9922637.x. [DOI] [PubMed] [Google Scholar]
  4. Buck C. E., Clark M. A., Debonneval M. C., Ewing A. A., Havey I. M., Pomeroy C., Pierce K. E., Randall M., Steeves M., Tattershall L. M. Record Forms for Public Health Nursing. Am J Public Health Nations Health. 1933 May;23(5):473–475. doi: 10.2105/ajph.23.5.473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Callea V., Morabito F., Luise F., Piromalli A., Filangeri M., Stelitano C., Iacopino P., Nobile F., Brugiatelli M. Clinical significance of sIL2R, sCD23, sICAM-1, IL6 and sCD 14 serum levels in B-cell chronic lymphocytic leukemia. Haematologica. 1996 Jul-Aug;81(4):310–315. [PubMed] [Google Scholar]
  6. Carrera C. J., Terai C., Lotz M., Curd J. G., Piro L. D., Beutler E., Carson D. A. Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy. J Clin Invest. 1990 Nov;86(5):1480–1488. doi: 10.1172/JCI114865. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cheson B. D., Bennett J. M., Grever M., Kay N., Keating M. J., O'Brien S., Rai K. R. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996 Jun 15;87(12):4990–4997. [PubMed] [Google Scholar]
  8. Cordingley F. T., Bianchi A., Hoffbrand A. V., Reittie J. E., Heslop H. E., Vyakarnam A., Turner M., Meager A., Brenner M. K. Tumour necrosis factor as an autocrine tumour growth factor for chronic B-cell malignancies. Lancet. 1988 Apr 30;1(8592):969–971. doi: 10.1016/s0140-6736(88)91782-5. [DOI] [PubMed] [Google Scholar]
  9. Emilie D., Leger-Ravet M. B., Devergne O., Raphael M., Peuchmaur M., Coumbaras J., Crevon M. C., Galanaud P. Intratumoral production of IL-6 in B cell chronic lymphocytic leukemia and B lymphomas. Leuk Lymphoma. 1993 Nov;11(5-6):411–417. doi: 10.3109/10428199309067934. [DOI] [PubMed] [Google Scholar]
  10. Hawley R. G. Hematopathology of interleukin 6-type cytokines. Stem Cells. 1994;12 (Suppl 1):155–171. [PubMed] [Google Scholar]
  11. Heaney M. L., Golde D. W. Soluble cytokine receptors. Blood. 1996 Feb 1;87(3):847–857. [PubMed] [Google Scholar]
  12. Huang R. W., Tsuda H., Takatsuki K. Interleukin-2 prevents programmed cell death in chronic lymphocytic leukemia cells. Int J Hematol. 1993 Aug;58(1-2):83–92. [PubMed] [Google Scholar]
  13. Jansen J. H., Wientjens G. J., Willemze R., Kluin-Nelemans J. C. Production of tumor necrosis factor-alpha by normal and malignant B lymphocytes in response to interferon-alpha, interferon-gamma and interleukin-4. Leukemia. 1992 Feb;6(2):116–119. [PubMed] [Google Scholar]
  14. Jewell A. P., Worman C. P., Giles F. J., Goldstone A. H. Serum levels of TNF, IL-6 and sCD23 correlate with changes in lymphocyte count in patients with B-cell chronic lymphocytic leukaemia receiving interferon-alpha therapy. Leuk Lymphoma. 1997 Jan;24(3-4):327–333. doi: 10.3109/10428199709039020. [DOI] [PubMed] [Google Scholar]
  15. Jurlander J., Lai C. F., Tan J., Chou C. C., Geisler C. H., Schriber J., Blumenson L. E., Narula S. K., Baumann H., Caligiuri M. A. Characterization of interleukin-10 receptor expression on B-cell chronic lymphocytic leukemia cells. Blood. 1997 Jun 1;89(11):4146–4152. [PubMed] [Google Scholar]
  16. Kishimoto T., Akira S., Narazaki M., Taga T. Interleukin-6 family of cytokines and gp130. Blood. 1995 Aug 15;86(4):1243–1254. [PubMed] [Google Scholar]
  17. Koskela K., Pelliniemi T. T., Remes K., Rajamäki A., Pulkki K. Serum oncostatin M in multiple myeloma: association with prognostic factors. Br J Haematol. 1997 Jan;96(1):158–160. doi: 10.1046/j.1365-2141.1997.8522478.x. [DOI] [PubMed] [Google Scholar]
  18. Lahat N., Aghai E., Maroun B., Kinarty A., Quitt M., Froom P. Increased spontaneous secretion of IL-6 from B cells of patients with B chronic lymphatic leukaemia (B-CLL) and autoimmunity. Clin Exp Immunol. 1991 Aug;85(2):302–306. doi: 10.1111/j.1365-2249.1991.tb05723.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Lavabre-Bertrand T., Exbrayat C., Liautard J., Gaillard J. P., Baskevitch P. P., Poujol N., Duperray C., Bourquard P., Brochier J. Detection of membrane and soluble interleukin-6 receptor in lymphoid malignancies. Br J Haematol. 1995 Dec;91(4):871–877. doi: 10.1111/j.1365-2141.1995.tb05403.x. [DOI] [PubMed] [Google Scholar]
  20. Lorgeot V., Praloran V., Turlure P., Denizot Y. Concentrations of serum leukemia inhibitory factor (LIF) in patients with hematologic malignancies. Leukemia. 1997 Feb;11(2):311–312. doi: 10.1038/sj.leu.2400570. [DOI] [PubMed] [Google Scholar]
  21. Lust J. A., Donovan K. A., Kline M. P., Greipp P. R., Kyle R. A., Maihle N. J. Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine. 1992 Mar;4(2):96–100. doi: 10.1016/1043-4666(92)90043-q. [DOI] [PubMed] [Google Scholar]
  22. Mainou-Fowler T., Copplestone J. A., Prentice A. G. Effect of interleukins on the proliferation and survival of B cell chronic lymphocytic leukaemia cells. J Clin Pathol. 1995 May;48(5):482–487. doi: 10.1136/jcp.48.5.482. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Mainou-Fowler T., Prentice A. G. Modulation of apoptosis with cytokines in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma. 1996 May;21(5-6):369–377. doi: 10.3109/10428199609093434. [DOI] [PubMed] [Google Scholar]
  24. Müllberg J., Schooltink H., Stoyan T., Günther M., Graeve L., Buse G., Mackiewicz A., Heinrich P. C., Rose-John S. The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol. 1993 Feb;23(2):473–480. doi: 10.1002/eji.1830230226. [DOI] [PubMed] [Google Scholar]
  25. O'Brien S., del Giglio A., Keating M. Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood. 1995 Jan 15;85(2):307–318. [PubMed] [Google Scholar]
  27. Peters M., Müller A. M., Rose-John S. Interleukin-6 and soluble interleukin-6 receptor: direct stimulation of gp130 and hematopoiesis. Blood. 1998 Nov 15;92(10):3495–3504. [PubMed] [Google Scholar]
  28. Rai K. R., Sawitsky A., Cronkite E. P., Chanana A. D., Levy R. N., Pasternack B. S. Clinical staging of chronic lymphocytic leukemia. Blood. 1975 Aug;46(2):219–234. [PubMed] [Google Scholar]
  29. Rambaldi A., Bettoni S., Rossi V., Tini M. L., Giudici G., Rizzo V., Bassan R., Mantovani A., Barbui T., Biondi A. Transcriptional and post-transcriptional regulation of IL-1 beta, IL-6 and TNF-alpha genes in chronic lymphocytic leukaemia. Br J Haematol. 1993 Feb;83(2):204–211. doi: 10.1111/j.1365-2141.1993.tb08273.x. [DOI] [PubMed] [Google Scholar]
  30. Robak E., Sysa-Jedrzejowska A., Stepień H., Robak T. Circulating interleukin-6 type cytokines in patients with systemic lupus erythematosus. Eur Cytokine Netw. 1997 Sep;8(3):281–286. [PubMed] [Google Scholar]
  31. Robak T., Błasińska-Morawiec M., Błoński J. Z., Krykowski E., Komarnicki M., Trepińska E., Kaźmierczuk M., Hansz J., Dmoszyńska A., Roliński J. The effect of 2-h infusion of 2-chlorodeoxyadenosine (cladribine) with prednisone in previously untreated B-cell chronic lymphocytic leukaemia. Eur J Cancer. 1997 Dec;33(14):2347–2351. doi: 10.1016/s0959-8049(97)00349-3. [DOI] [PubMed] [Google Scholar]
  32. Robak T., Gladalska A., Stepień H., Robak E. Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis. Mediators Inflamm. 1998;7(5):347–353. doi: 10.1080/09629359890875. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Robinson R. C., Grey L. M., Staunton D., Vankelecom H., Vernallis A. B., Moreau J. F., Stuart D. I., Heath J. K., Jones E. Y. The crystal structure and biological function of leukemia inhibitory factor: implications for receptor binding. Cell. 1994 Jul 1;77(7):1101–1116. doi: 10.1016/0092-8674(94)90449-9. [DOI] [PubMed] [Google Scholar]
  34. Rozman C., Montserrat E. Chronic lymphocytic leukemia. N Engl J Med. 1995 Oct 19;333(16):1052–1057. doi: 10.1056/NEJM199510193331606. [DOI] [PubMed] [Google Scholar]
  35. Saito M., Yoshida K., Hibi M., Taga T., Kishimoto T. Molecular cloning of a murine IL-6 receptor-associated signal transducer, gp130, and its regulated expression in vivo. J Immunol. 1992 Jun 15;148(12):4066–4071. [PubMed] [Google Scholar]
  36. Seymour J. F., Kurzrock R., Freireich E. J., Estey E. H. 2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood. 1994 May 15;83(10):2906–2911. [PubMed] [Google Scholar]
  37. Touw I., Dorssers L., Löwenberg B. The proliferative response of B cell chronic lymphocytic leukemia to interleukin 2: functional characterization of the interleukin 2 membrane receptors. Blood. 1987 Jun;69(6):1667–1673. [PubMed] [Google Scholar]
  38. Trentin L., Zambello R., Agostini C., Enthammer C., Cerutti A., Adami F., Zamboni S., Semenzato G. Expression and regulation of tumor necrosis factor, interleukin-2, and hematopoietic growth factor receptors in B-cell chronic lymphocytic leukemia. Blood. 1994 Dec 15;84(12):4249–4256. [PubMed] [Google Scholar]
  39. Trentin L., Zambello R., Agostini C., Siviero F., Adami F., Marcolongo R., Raimondi R., Chisesi T., Pizzolo G., Semenzato G. Expression and functional role of tumor necrosis factor receptors on leukemic cells from patients with type B chronic lymphoproliferative disorders. Blood. 1993 Feb 1;81(3):752–758. [PubMed] [Google Scholar]
  40. Wang X. J., Taga T., Yoshida K., Saito M., Kishimoto T., Kikutani H. gp130, the cytokine common signal-transducer of interleukin-6 cytokine family, is downregulated in T cells in vivo by interleukin-6. Blood. 1998 May 1;91(9):3308–3314. [PubMed] [Google Scholar]
  41. Wierzbowska A., Urbańska-Ryś H., Robak T. Circulating IL-6-type cytokines and sIL-6R in patients with multiple myeloma. Br J Haematol. 1999 May;105(2):412–419. [PubMed] [Google Scholar]
  42. Yasukawa K., Futatsugi K., Saito T., Yawata H., Narazaki M., Suzuki H., Taga T., Kishimoto T. Association of recombinant soluble IL-6-signal transducer, gp130, with a complex of IL 6 and soluble IL-6 receptor, and establishment of an ELISA for soluble gp130. Immunol Lett. 1992 Feb;31(2):123–130. doi: 10.1016/0165-2478(92)90138-e. [DOI] [PubMed] [Google Scholar]
  43. Zhang X. G., Klein B., Bataille R. Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood. 1989 Jul;74(1):11–13. [PubMed] [Google Scholar]
  44. van Kooten C., Rensink I., Aarden L., van Oers R. Effect of IL-4 and IL-6 on the proliferation and differentiation of B-chronic lymphocytic leukemia cells. Leukemia. 1993 Apr;7(4):618–624. [PubMed] [Google Scholar]

Articles from Mediators of Inflammation are provided here courtesy of Wiley

RESOURCES